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Abstract
Objectives The aim of the study was to investigate the impact of two hyaluronan (HA) formulations on the osteogenic potential
of osteoblast precursors.
Materials and methods Proliferation rates of HA-treated mesenchymal stromal ST2 and pre-osteoblastic MC3T3-E1 cells were
determined by 5-bromo-20-deoxyuridine (BrdU) assay. Expression of genes encoding osteogenic differentiation markers, critical
growth, and stemness factors as well as activation of downstream signaling pathways in the HA-treated cells were analyzed by
quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and immunoblot techniques.
Results The investigated HAs strongly stimulated the growth of the osteoprogenitor lines and enhanced the expression of genes
encoding bone matrix proteins. However, expression of late osteogenic differentiation markers was significantly inhibited,
accompanied by decreased bone morphogenetic protein (BMP) signaling. The expression of genes encoding transforming
growth factor-β1 (TGF-β1) and fibroblast growth factor-1 (FGF-1) as well as the phosphorylation of the downstream signaling
molecules Smad2 and Erk1/2 were enhanced uponHA treatment.We observed significant upregulation of the transcription factor
Sox2 and its direct transcription targets and critical stemness genes, Yap1 and Bmi1, in HA-treated cells. Moreover, prominent
targets of the canonical Wnt signaling pathway showed reduced expression, whereas inhibitors of the pathway were considerably
upregulated.We detected decrease of activeβ-catenin levels in HA-treated cells due toβ-catenin being phosphorylated and, thus,
targeted for degradation.
Conclusions HA strongly induces the growth of osteoprogenitors and maintains their stemness, thus potentially regulating the
balance between self-renewal and differentiation during bone regeneration following reconstructive oral surgeries.
Clinical relevance Addition of HA to deficient bone or bony defects during implant or reconstructive periodontal surgeries may
be a viable approach for expanding adult stem cells without losing their replicative and differentiation capabilities.
Keywords Hyaluronicacid .Boneandsoft tissueregeneration .Stemness .Growthfactors .Extracellularmatrix .Geneexpression
Introduction
Due to its hygroscopic and viscoelastic properties as well as its
high biocompatibility and non-immunogenic nature, hyaluronan
(HA) has been utilized in various regenerative medical and tissue
engineering applications [1]. HA is an anionic, non-sulfated gly-
cosaminoglycan and a key component of the extracellular matrix
(ECM) of vertebrate tissues. Contents of approximately 1–
100 μg HA/g wet tissue weight were reported for most organs
[2]. Measurements of HA content represent high interest since
changes in HA content are often correlated with tissue remodel-
ing and pathological processes [3]. HA is particularly prominent
in non-mineralized periodontal tissues such as gingiva and peri-
odontal ligament [4] compared to the lower quantities found in
mineralized tissues such as cementum [5] and alveolar bone [6].
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00784-020-03259-8) contains supplementary
material, which is available to authorized users.
* Maria B. Asparuhova
mariya.asparuhova@zmk.unibe.ch
1 Laboratory of Oral Cell Biology, Dental Research Center, School of
Dental Medicine, University of Bern, Freiburgstrasse 3,
3010 Bern, Switzerland
2 Department of Oral Surgery and Stomatology, School of Dental
Medicine, University of Bern, Freiburgstrasse 7,
3010 Bern, Switzerland
3 Department of Periodontology, School of Dental Medicine,
University of Bern, Freiburgstrasse 7, 3010 Bern, Switzerland
https://doi.org/10.1007/s00784-020-03259-8
/ Published online: 31 March 2020
Clinical Oral Investigations (2020) 24:3923–3937
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
7
1
8
3
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
HA is involved in numerous biological processes related to
tissue regeneration, such as regulation of cell adhesion, migra-
tion and proliferation, manipulation of cell differentiation, and
mediation of cell signaling [7]. In addition, it exhibits anti-
inflammatory [8], pro-angiogenic [9], and osteoinductive
properties [10]. Although HA is a key component in the series
of events associated with the wound healing process, i.e., in-
flammation, granulation tissue formation, epithelium forma-
tion, and tissue remodeling, detailed mechanisms of action
remain largely uncovered and often controversial, especially
in the healing of oral mineralized tissues following periodon-
tal regenerative procedures and implant surgeries. It has been
reported that the effect of HA on cellular proliferation and
osteogenic differentiation in vitro largely depends on its mo-
lecular weight (MW) and concentration. Low MW HA (<
700 kDa) was mostly reported to stimulate cellular prolifera-
tion in calvaria- or tibia/femur condyle-derived mesenchymal
cell cultures [11–13]. However, the effect of highMWHA (>
1000 kDa) on cellular proliferation is disputable. Some studies
demonstrated that high MW HA promoted cellular adhesion
and proliferation in a dose-dependent manner in rat calvarial
mesenchymal [12] and human periodontal ligament [14] cell
cultures, whereas others reported inhibition of cell growth in
diverse cell types [11, 15, 16]. The effect of high MW HA on
cellular differentiation is also open to question. HighMWHA
has been shown to significantly induce osteocalcin mRNA
expression, mineralization, and alkaline phosphatase activity
in rat calvarial-derived cell cultures, in a concentration-
dependent manner [12]. In contrast, either no effect of high
MWHA onmRNA expressions of bone-related genes in peri-
odontal ligament cells [14] or even significant inhibition of the
osteogenic differentiation of both mouse myoblastic and
mouse mesenchymal cells, have been reported [16]. In vitro
studies have shown that low MW HA exhibits osteogenic
activity, both through the intramembranous and the endochon-
dral paths of osteogenesis [11, 17].
In vivo, application of HA for bone regeneration has been
demonstrated in craniofacial bone defects in various animal
models [18]. To stimulate bone formation, HA is either (1)
mixed with filler materials [9, 10, 19–21], (2) applied as a
coating material [22], or (3) used as a carrier of growth factors
and cells in the bone defect [23–25]. However, to date, only
few clinical studies exist on the use of HA in reconstructive
periodontal surgery [26–30]. Before conducting such clinical
studies, a better understanding is needed of the influence of
HA on the tissues comprising the periodontium, i.e., cemen-
tum, alveolar bone, periodontal ligament, and gingival con-
nective tissue. In a recent study, we have demonstrated diverse
positive effects of two commercially available HA formula-
tions on primary human palatal and gingival fibroblasts, two
cell types involved in soft tissue healing/regeneration follow-
ing periodontal reconstructive therapies that utilize palatal
connective tissue or free gingival grafts [31]. The observed
pro-proliferative, pro-migratory, and pro-wound healing prop-
erties of the two HAs speak in favor of their clinical potential.
Based upon these data, the goal of the present study was to
investigate the effects of the two HAs on the growth of the
mesenchymal stromal line, ST2 as well as the osteoprogenitor
cell line, MC3T3-E1. The two commercially available HA
preparations, planned to be used in reconstructive periodontal
surgery, are considered high MW (≥ 1000 kDa) and appear
close to the physiological HA found in many biological fluids
and solid tissues [3]. The study further aimed to investigate the
osteogenic response induced by the HAs in the two cell lines,
thus providing insights into the mechanisms involved in HA-
controlled osteogenesis and the clinical potential of the two
HA formulations.
Materials and methods
Cell culture and HA preparations
Mesenchymal stromal ST2 cells (RIKEN; Tsukuba, Japan)
and osteoblast progenitor MC3T3-E1 cells (ATCC, CRL-
2593; Manassas, VA, USA) were grown in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS; Invitrogen, Zug, Switzerland). For differ-
entiation experiments, media were supplemented with
50 μg/ml ascorbic acid (Invitrogen) and 2 mM β-
glycerophosphate (Invitrogen) as described [32].
The investigated HA formulations were kindly provided by
Regedent AG (Zurich, Switzerland) and previously described
[31]. In brief, HA1 (hyaDENT) is a native non-crosslinked
HAwith MWof 2500 kDa, whereas HA2 (hyaDENT BG) is
a formulation containing complexes of butanediol diglycidyl
ether (BDDE)-crosslinked 1000 kDa-HA monomers and the
above non-crosslinked form. Throughout the study, HA was
used at a final concentration of 4 mg/ml in 0.3%FBS/DMEM
as previously described [31]. The concentration was chosen
based on (1) pilot experiments (data not shown) comparing
4 mg/ml-diluted HAs with the undiluted commercial prepara-
tions and (2) the assumption that each of the HA preparations
will be naturally diluted by patients’ blood and saliva during
the periodontal surgical procedure. In brief, for RNA analyses,
cells were plated at 3 × 104 cells/cm2 on HA-coated plates for
24 h. For protein analyses, 6 h after seeding at the same den-
sity, the adherent cells were starved in 0.3% FBS/DMEM for
18 h and then treated with HA for 30 min.
Cell proliferation assay
Proliferation rates of HA-treated ST2 and MC3T3-E1 cells
were determined using a 5-bromo-20-deoxyuridine (BrdU)
chemiluminescent ELISA assay (Roche, Basel, Switzerland)
as described [31, 33]. In brief, after 24 h of starvation, cells
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were plated in triplicate at 2 × 103 cells/well in 3% FBS/
DMEM on Black 96-well microtiter plates (Thermo Fisher
Scientific, Reinach, Switzerland) coated with HA at a final
concentration of 4 mg/ml. Cells were allowed to proliferate
for 0, 24, 48, 72, and 96 h before labeling with BrdU for 2 h.
BrdU uptake into newly synthesized DNA was determined
according to manufacturer’s instructions using a luminometer
Infinite® 200 (Tecan, Männedorf, Switzerland). Experimental
values were normalized to the values of untreated control cells
at the time point 0. Data represent means ± SD from three
independent experiments.
RNA analyses by qRT-PCR
Total RNA from HA-treated ST2 and MC3T3-E1 cells was
isolated using the RNeasy Mini Kit (Qiagen, Basel,
Switzerland). RNA, quantified on a NanoDrop 2000c
(Thermo Fisher Scientific) instrument, was reverse tran-
scribed, and relative transcripts for the osteogenic differentia-
tion marker genes Col1a1, Col1a2, Spp1, Runx2, Bglap2,
Ibsp, and Alpl, normalized to Gapdh, were measured using
qRT-PCR as previously described [32]. Additionally, relative
transcripts for Bmp2, Bmp4, Bmp7, Tgfb1, Fgf1, Sox2, Yap1,
Bmi1, Ctgf, Ccnd1, Dkk1, Apc, and Gsk3b genes, normalized
to Gapdh, were measured using FastStart Universal SYBR
Green Master ROX (Roche) and the primer sequences listed
in Electronic Supplementary Material, Table S1. qPCR was
carried out in a 7500 Real-Time PCR System (Applied
Biosystems, Rotkreuz, Switzerland) using a standard thermal
cycling profile. Data were analyzed using the efficiency ΔΔCt
method [34]. All samples were run in duplicates. Data repre-
sent means ± SD from three independent experiments.
Protein analyses by Western blot
Whole-cell extracts from HA-treated ST2 and MC3T3-E1
cells were prepared by lysis in radioimmunoprecipitation as-
say (RIPA) buffer as previously described [35]. Lysates were
run on 10% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to Amersham™
Protran® membrane (Sigma, Buchs, Switzerland).
Visualization of proteins of interest was achieved by using
anti-phospho-Smad1/5/8 (Cell Signaling Technology,
Leiden, The Netherlands), anti-Smad1 (Cell Signaling
Technology), anti-phospho-Smad2 (Thermo Fisher
Scientific), anti-Smad2, anti-phospho-Erk1/2, anti-Erk, anti-
active β-catenin, anti-phospho-β-catenin (all from Cell
Signaling Technology), anti-vinculin (Sigma), and anti-
GAPDH (abcam, Cambridge, UK) antibodies followed by
horseradish peroxidase-conjugated secondary antibodies
(MP Biomedicals, Santa Ana, CA, USA) for detection with
the SuperSignal™ West Dura Substrate (Thermo Fisher
Scientific). Immunoblot signals were analyzed by
densitometry using ImageQuant Software (Molecular
Dynamics, Groningen, the Netherlands). Data represent
means ± SD from three independent experiments.
Statistical analysis
All grouped data are means ± SD. Statistical analysis was
completed using GraphPad InStat Software, version 3.05.
Multiple comparisons were performed using one-way analysis
of variance (ANOVA) with Tukey’s post-hoc test. Values of
P < 0.05 were considered significant.
Results
The two HA preparations strongly stimulate
the growth of ST2 and MC3T3-E1 cells and enhance
the expression of genes encoding bone matrix
proteins
We have previously shown that coating of cell culture plates
with the non-crosslinked formulation of HA (HA1) resulted in
the formation of a continuous uniform gel layer, whereas coat-
ing with the BDDE-crosslinked formulation of HA (HA2)
resulted in the formation of HA meshes [31]. Thus, the two
adherent cell lines ST2 and MC3T3-E1, both utilized in the
study as a progenitor source of osteoblasts, were able to ad-
here onHA1-coated plates and their morphology did not differ
from the morphology of untreated cells seeded on non-coated
cell culture plastic (Electronic Supplementary Material, Fig.
S1). In contrast, in the case of HA2, the two cell lines appeared
to adhere solely on the cell culture plastic while HA2 was
present in suspension (Electronic Supplementary Material,
Fig. S1). Thus, due to the observed difference in the natural
occurrence of the two HAs and as in our previously published
research investigating the effects of the two HA formulations
[31], a further distinction between HA applied as a coating or
in suspension was not made and we refer to “HA treatment”
throughout the present study.
We first assessed the effects of the two HA preparations on
the proliferative rates of ST2 and MC3T3-E1 cells (Fig. 1a).
Compared to untreated control cells, ST2 cells treated with
either HA1 or HA2 showed a significant increase in BrdU
uptake into newly synthesized DNA until they reached con-
fluence approximately 65 h later (Fig. 1a, left panel).
Interestingly, the proliferative rate of MC3T3-E1 cells treated
with HA2 was greatly increased by 11.7-fold above the pro-
liferative rate detected in control cells within the first 24 h
(Fig. 1a, right panel, green line). An induction of 7.1-fold
compared to control cells was observed in MC3T3-E1 cells
treated with HA1 within 48 h (Fig. 1a, right panel, red line).
To assess the osteogenic potential of the two HA prepara-
tions, we monitored the expression of genes encoding bone
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matrix proteins such as collagen type I (Col1a1 and Col1a2)
and osteopontin (also known as secreted phosphoprotein 1,
Spp1) in HA-treated ST2 and MC3T3-E1 cells. Both HAs
caused a significant increase in Col1a1, Col1a2, and Spp1
mRNAs above the expression levels detected in control cells
(Fig. 1b). The crosslinked-HA2 formulation appeared more
potent than the non-crosslinked HA1 and induced a signifi-
cantly higher expression of the three bone matrix protein-
coding genes in MC3T3-E1 cells as well as a higher expres-
sion of Col1a1 and Spp1 in ST2 cells.
The obtained data indicate a strong positive impact of the
two HA formulations on the growth of ST2 and MC3T3-E1
cells. Furthermore, the data suggest a substantial positive im-
pact of HA on the early stages of differentiation, namely ma-
trix production. For both investigated functionalities, the
crosslinked HA2 formulation appeared slightly more potent
than the non-crosslinked HA1, especially in MC3T3-E1 pre-
osteoblasts.
The two HA preparations inhibit the expression
of intermediate and late osteogenic differentiation
markers as well as BMP-induced Smad signaling
in ST2 and MC3T3-E1 cells
To further assess the osteogenic potential of HA, we moni-
tored the expression of genes encoding intermediate and late
differentiation markers such as runt-related transcription fac-
tor 2 (Runx2), osteocalcin (or bone gamma-carboxyglutamate
protein 2, Bglap2), bone sialoprotein (or integrin-binding
sialoprotein, Ibsp), and alkaline phosphatase (Alpl) in HA-
treated ST2 and MC3T3-E1 cells. Both HA preparations
caused a strong and significant inhibition of all four differen-
tiation markers in both progenitor cell lines compared to con-
trol cells (Fig. 2a, b). In ST2 cells, HA1 appeared to be slightly
but significantly more potent (by 1.6-fold, P < 0.05) than HA2
in suppressing Bglap2 expression (Fig. 2a). In agreement with
the gene expression analysis, the mineral deposition capacity
Fig. 1 The two HA preparations
strongly stimulate the growth of
ST2 and MC3T3-E1 cells and
enhance the expression of genes
encoding bone matrix proteins. a
Proliferation rates of HA-treated
ST2 and MC3T3-E1 cells were
assessed by BrdU incorporation
into newly synthesized DNA
immediately after plating (0 h) as
well as at 24, 48, 72, and 96 h.
Means ± SD from three
independent experiments and
significant differences to
untreated control (Ctrl) cells at the
time point 0; ***P < 0.001 and
*P < 0.05 are shown. b Effect of
HA1 and HA2 on Col1a1,
Col1a2, and Spp1 mRNA levels
in ST2 and MC3T3-E1 cells.
Cells were treated with each of the
two HA preparations for 24 h
before total RNAwas extracted
and analyzed by qRT-PCR.
Values normalized to Gapdh are
expressed relative to the values of
control (Ctrl) cells. Data represent
means ± SD from three
independent experiments.
Significant differences to the
respective control unless
otherwise indicated, ***P <
0.001, **P < 0.01, *P < 0.05
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of HA-treated ST2 andMC3T3-E1 cells was strongly reduced
as detected by alizarin red stain (Electronic Supplementary
Material, Fig. S2). The obtained data strongly suggest an
inhibited progression of HA-treated cells to the next stages
of osteoblast differentiation, namely maturation of the ECM
with alkaline phosphatase and subsequent matrix
mineralization.
In agreement with these data, we observed strong down-
regulation of Smad1/5/8 signaling in HA-treated ST2 and
MC3T3-E1 cells (Fig. 3a, b). Compared to the basal levels
of phospho-Smad1/5/8 detected in control cells of the two
progenitor lines, the phosphorylation of Smad1/5/8 protein
significantly decreased by approximately 3-fold in cells treat-
ed with each of the two HA preparations (Fig. 3b).
Smad1, 5, and 8 are receptor-regulated transcription factors
(R-Smads) activated by BMPs [36]. BMPs induce Runx2 ex-
pression in mesenchymal progenitor cells namely through the
action of R-Smads [37], and R-Smads in turn interact with
Fig. 2 The two HA preparations
inhibit the expression of
intermediate and late osteogenic
differentiation markers as well as
BMP-induced Smad signaling in
ST2 and MC3T3-E1 cells. a, b
Effect of HA1 and HA2 on
Runx2, Bglap2, Ibsp, and Alpl
mRNA levels in ST2 (a) and
MC3T3-E1 (b) cells. Each of the
two cell lines was treated with
HA1 or HA2 preparations for
24 h before total RNAwas
extracted and analyzed by qRT-
PCR. Values normalized to
Gapdh are expressed relative to
the values of untreated control
(Ctrl) cells. Data represent means
± SD from three independent
experiments. Significant
differences to the respective
control unless otherwise
indicated, ***P < 0.001, **P <
0.01, *P < 0.05
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Runx2 to regulate the transcription of target genes leading to
osteoblast differentiation [38]. HA-treated ST2 and MC3T3-
E1 cells were further characterized by decreased expression of
Bmp2, 4, and 7 genes, encoding three osteogenic BMPs (Fig.
3c). Taken together, our data indicate that the two HA prepa-
rations negatively regulate the BMP-Runx2 axis involved in
osteogenic differentiation.
The two HA preparations significantly enhance
the expression of genes encoding TGF-β1 and FGF-1
as well as the phosphorylation of Smad2 and Erk1/2
signaling molecules in ST2 and MC3T3-E1 cells
Several lines of evidence indicate that TGF-β1 and FGFs
regulate proliferation and differentiation in osteoblasts [39,
40]. To investigate how HA increases the proliferation and
bone matrix production in ST2 and MC3T3-E1 progenitor
cells but blocks their differentiation into mature osteoblasts,
we tested the expression of genes encoding TGF-β1 and FGF-
1 in HA-treated cells of the two lines. We chose FGF-1 as a
ligand that binds all FGF receptor isoforms [41]. qRT-PCR
analyses revealed a significant induction of both growth fac-
tors in ST2 and MC3T3-E1 cells exposed to each of the two
HAs compared to basal expression levels detected in control
cells (Fig. 4a). No trend for a difference in efficacy between
the two HA formulations was observed.
To gain insights into the mechanisms whereby the two HAs
exert their effects on growth factor gene expression in the
osteoblast precursor cell lines, we investigated the activation
state of two signaling molecules, Smad2 and Erk1/2 by
Fig. 3 The two HA preparations inhibit BMP-activated Smad signaling
in ST2 and MC3T3-E1 cells. a, b Immunoblot analysis of phospho-
Smad1/5/8 (pSmad1/5/8) protein (a) in whole-cell extracts from ST2
and MC3T3-E1 cells treated with each of the two HA preparations.
Blots for total Smad1 protein as well as the vinculin loading control are
also shown a. The bar chart (b) represents densitometric quantification of
the immunoblots. pSmad1/5/8 levels are normalized to the total Smad1
protein used as internal control. Data represent means ± SD from three
independent experiments. Significant differences to the respective control
(Ctrl) cells of each of the two cell lines, ***P < 0.001, **P < 0.01. c
Effect of HA1 and HA2 on Bmp2, Bmp4, and Bmp7 mRNA levels in
ST2 and MC3T3-E1 cells. Cells were treated with each of the two HA
preparations for 24 h before total RNA was extracted and analyzed by
qRT-PCR. Values normalized to Gapdh are expressed relative to the
values of control (Ctrl) cells. Data represent means ± SD from three
independent experiments. Significant differences to the respective con-
trol, ***P < 0.001, **P < 0.01, *P < 0.05, ns = not significant
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immunoblotting. Smad2 responds to TGF-β1 [36], whereas
FGFs often signal through the mitogen-activated protein ki-
nase (MAPK) Erk1/2 [42]. Compared to the basal levels of
phospho-Smad2 and phospho-Erk1/2 detected in control cells,
phosphorylation of each of the two proteins significantly in-
creased in both ST2 and MC3T3-E1cells treated with either
HA formulation for 30 min (Fig. 4b, c). In particular, the
phosphorylation of the TGF-β1-specific Smad2 in HA-
treated cells was upregulated between 5.8- and 7.0-fold
compared to control cells (Fig. 4b), whereas the phosphoryla-
tion of Erk1/2 increased by 3.0–5.7-fold (Fig. 4c).
The two HA preparations induce expression
of the transcription factor Sox2 and its direct targets
Yap1 and Bmi1 in ST2 and MC3T3-E1 cells
Earlier studies have established a mechanistic link between
expression of the transcription factor Sox2 and FGF or
Fig. 4 The two HA preparations significantly enhance the expression of
genes encoding TGF-β1 and FGF-1 growth factors as well as the phos-
phorylation of Smad2 and Erk1/2 signaling molecules in ST2 and
MC3T3-E1 cells. a Effect of HA1 and HA2 on Tgfb1 and Fgf1 mRNA
levels in ST2 and MC3T3-E1 cells. Cells of each of the two lines were
treated with each of the two HA preparations for 24 h before total RNA
was extracted and analyzed by qRT-PCR. Values normalized to Gapdh
are expressed relative to the values of control (Ctrl) cells. Data represent
means ± SD from three independent experiments. Significant differences
to the respective control, ***P < 0.001, **P < 0.01, *P < 0.05. b, c
Immunoblot analyses of phospho-Smad2 (pSmad2) (b) and phospho-
Erk1/2 (pErk1/2) (c) proteins in whole-cell extracts from HA-treated
ST2 and MC3T3-E1 cells. Blots for total Smad2 and Erk1/2 proteins as
well as the vinculin loading control are also shown. The bar charts rep-
resent densitometric quantifications of the immunoblots. pSmad2 and
pErk1/2 levels are normalized to the respective total proteins used as
internal controls. Data represent means ± SD from three independent
experiments. Significant differences to the respective control (Ctrl) cells
of each of the two cell lines, ***P < 0.001, **P < 0.01
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TGF-β signaling in osteoblasts or cancer cells, respectively
[43–45]. Furthermore, Sox2 has been described as a negative
regulator of osteoblast differentiation and maturation in vivo
[46, 47]. Thus, to further dissect the mechanism underlying
the response of mesenchymal stromal and pre-osteoblastic
cells to HA, we tested the expression of Sox2 in HA-treated
ST2 and MC3T3-E1 cells, respectively. Compared to control
cells, either HA preparation upregulated the expression levels
of Sox2 in both cell lines (Fig. 5a).
Sox2, as a member of the high mobility group (HMO)
domain Sox family of transcription factors, is required to
maintain the stemness and self-renewal of embryonic [48] as
well as adult stem cells [49–51]. This prompted us to investi-
gate the influence of HA on the expression levels of two
critical stemness genes, Yap1 [52] and Bmi1 [53], which were
shown to be direct transcriptional targets of Sox2 in the oste-
oblast lineage [49, 50]. qRT-PCR analyses revealed that treat-
ment of the two progenitor cell lines with HA resulted in
increased Yap1 and Bmi1 mRNA levels above the levels
obtained in control cells (Fig. 5b). No trend for a more pro-
nounced effect of one or the other HA on the induction of
these two genes was observed.
Taken together, our data strongly suggest that the two HA
preparations maintain the self-renewal (stemness) potential of
mesenchymal stromal ST2 and pre-osteoblastic MC3T3-E1
cells.
The two HA preparations inhibit Wnt signaling in ST2
and MC3T3-E1 cells
The canonical Wnt signaling pathway promotes differentia-
tion in osteoprogenitor cells [54, 55]. Furthermore, the inhib-
itory effect of Sox2 on the osteogenic differentiation has been
partially explained by interfering with Wnt signaling [43, 56].
Thus, inhibited Wnt signaling could potentially provide a
mechanistic explanation for the inhibited expression of osteo-
genic differentiation markers in HA-treated ST2 and MC3T3-
E1 cells. We first tested the influence of HA on the expression
Fig. 5 The two HA preparations
induce expression of the
transcription factor Sox2 and its
direct targets Yap1 and Bmi1 in
ST2 and MC3T3-E1 cells. a, b
Effect of HA1 and HA2 on Sox2
(a), Yap1, and Bmi1 (b) mRNA
levels in ST2 and MC3T3-E1
cells. Cells were treated with each
of the two HA preparations for
24 h before total RNAwas
extracted and analyzed by qRT-
PCR. Values normalized to
Gapdh are expressed relative to
the values of control (Ctrl) cells.
Data represent means ± SD from
three independent experiments.
Significant differences to the
respective control, ***P < 0.001,
**P < 0.01, *P < 0.05
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of two prominentWnt target genes, Ctgf and Ccnd1, encoding
connective tissue growth factor and cyclin D1 protein, respec-
tively. Our results showed a very significant (P < 0.001)
downregulation of the two genes upon HA treatment of the
two cell lines compared to control cells (Fig. 6a). In contrast,
negative Wnt regulators such as Dkk1, Apc, and Gsk3b,
encoding the dickkopf-related protein 1, adenomatous
polyposis coli, and glycogen synthase kinase 3 beta, respec-
tively, were significantly upregulated by each of the two HAs
compared to their basal expression levels in control cells (Fig.
6b). In isolated cases, one HA formulation appeared to be
more potent than the other, e.g., HA1 caused a significantly
stronger downregulation of Ctgf mRNA (Fig. 6a, upper left
panel), whereas HA2 more strongly induced Apc expression
in ST2 cells (Fig. 6b, middle left panel).
To gain further insight into the mechanism determining the
inhibitory effect of HA on the Wnt signaling and osteoblast
differentiation of ST2 and MC3T3-E1 cells, we monitored the
Fig. 6 The two HA preparations
influence the expression of genes
involved in the Wnt signaling
pathway in ST2 and MC3T3-E1
cells. a HA downregulates the
mRNA expression levels of two
Wnt target genes, Ctgf and
Ccnd1, encoding connective
tissue growth factor and cyclin D1
protein, respectively. ST2 and
MC3T3-E1 cells were treated
with each of the two HA
preparations for 24 h before total
RNAwas extracted and analyzed
by qRT-PCR. Values normalized
to Gapdh are expressed relative to
the values of control (Ctrl) cells.
Data represent means ± SD from
three independent experiments.
Significant differences to the
respective control unless
otherwise indicated, ***P <
0.001, **P < 0.01. b HA
upregulates the mRNA
expression levels of three Wnt
inhibitors, Dkk1, Apc, and
Gsk3b, encoding the dickkopf-
related protein 1, adenomatous
polyposis coli, and glycogen
synthase kinase 3 beta protein,
respectively. Cells were treated as
in a before mRNA levels of the
respective genes were analyzed
by qRT-PCR. Values normalized
to Gapdh are expressed relative to
the values of control (Ctrl) cells.
Data represent means ± SD from
three independent experiments.
Significant differences to the
respective control unless
otherwise indicated, ***P <
0.001, **P < 0.01, *P < 0.05
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levels of active non-phosphorylated as well as phosphorylated
β-catenin protein on two consecutive days after HA treatment
(Fig. 7). In the absence of a Wnt stimulus, β-catenin is con-
stitutively phosphorylated by GSK3β and then targeted for
degradation by ubiquitination [57]. On the contrary, when
GSK3β activity is inhibited by Wnt, non-phosphorylated β-
catenin accumulates in the cell cytoplasm followed by its
translocation into the nucleus [58]. There, β-catenin acts as
a transcriptional coactivator for a family of transcription fac-
tors, which are otherwise bound to DNA in a repressive com-
plex not permitting the expression of Wnt target genes [59].
Short treatment with each of the two HA preparations resulted
in a slight but not significant decrease in the levels of activeβ-
catenin protein in each of the two cell lines after 24 h.
However, on day 2 after the treatment, active β-catenin levels
were strongly reduced by 2.3–3.8- and 3.5–6.5-fold in HA-
treated ST2 and MC3T3-E1 cells, respectively, compared to
the respective control cells (Fig. 7a, b). In contrast, β-catenin
phosphorylation was significantly enhanced by the HA prep-
arations in each of the two cell lines on day 1 and remained
induced on day 2 after the treatment (Fig. 7c, d), suggesting a
role of HA in targeting β-catenin for degradation.
These results indicate that along with the described down-
regulation of BMP-induced Smad signaling, the two HA
Fig. 7 The two HA preparations
inhibit Wnt signaling in ST2 and
MC3T3-E1 cells. a–d
Immunoblots of active β-catenin
(a, b) and phospho-β-catenin (c,
d) proteins in whole-cell extracts
of ST2 and MC3T3-E1 cells
treated with each of the two HA
preparations. Cell lysates were
collected on two consecutive days
after the treatment. Anti-GAPDH
served as loading control.
Densitometric analyses (b, d) of
the immunoblots shown in a and
c. Active β-catenin (a, b) and
phospho-β-catenin (c, d) protein
levels are normalized to the
GAPDH loading controls. Means
± SD from three independent
experiments and significant
differences to the respective
control (Ctrl) cells, ***P < 0.001,
**P < 0.01, *P < 0.05 are shown.
No statistically significant
differences between identically
treated cells on days 1 and 2 after
the stimulation were detected
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preparations cause inhibition of Wnt signaling, which ulti-
mately contributes to the prominent role of HA in maintaining
the self-renewal capabilities of mesenchymal stromal and
osteoprogenitor cells.
Discussion
HA is a key structural element in both mineralized and non-
mineralized periodontal tissues, such as alveolar bone and
cementum [5, 6], gingiva, and periodontal ligament [4]. The
unique hygroscopic and viscoelastic properties of HA contrib-
ute to the series of events associated with the soft tissuewound
healing process in periodontal regeneration [60]. Based on the
fact that wound healing in different tissues follow similar bi-
ological principles, it is conceivable that HA has comparable
roles in the healing of the mineralized tissues of the periodon-
tium. In a recent study, we investigated the role of two HA
formulations on the cellular behavior and wound healing
properties of primary human palatal and gingival fibroblasts
as the two major cell types involved in soft tissue healing/
regeneration following periodontal reconstructive therapies
[31]. Bone marrow–derived mesenchymal stromal cells as
well as calvaria-derived pre-osteoblasts are widely used to
study osteogenic differentiation in vitro and to gain an insight
into the mechanisms driving the bone healing process. Thus,
the objective of the present study was to evaluate the effects of
the two HA preparations on the osteogenic potential of ST2
mesenchymal stromal and MC3T3-E1 pre-osteoblastic cell
lines.
Our data, summarized in Fig. 8, demonstrated that the two
HAs exhibit multiple actions on the functionalities of the two
cell lines. First, we could show that HA strongly stimulates the
proliferation of the two progenitor lines and enhances the ex-
pression of genes encoding proteins typical for yet uncalcified
bone matrix, suggesting a potent role of HA in increasing the
pool of committed osteoblasts and in triggering the early
stages of the differentiation, namely bone matrix production.
Second, we demonstrated a prominent role of HA inmaintain-
ing the stemness of mesenchymal stromal and pre-osteoblastic
cells by acting on several different levels: (1) downregulation
of BMP-induced Smad signaling, (2) induction of the
Fig. 8 Model for the effects of the two investigated HA formulations on
the behavior and functionality of mesenchymal stromal ST2 and pre-
osteoblastic MC3T3-E1 cells. Treatment of each of the two cell lines,
used as a progenitor source of osteoblasts, with HA (a structural formula
is presented) results in induced cellular proliferation and bone matrix
production, as suggested by the upregulated expression of Col1a1,
Col1a2, and Spp1 genes encoding bone matrix proteins. These effects
are accompanied and likely influenced by induced TGF-β and FGF sig-
naling in the HA-treated cells. Signaling through both BMP-induced
Smad and Wnt pathways is strongly downregulated upon HA treatment,
which results in inhibited progression of the osteogenic differentiation as
evidenced by decreased expression of intermediate and late osteogenic
differentiation marker genes such as Runx2, Bglap2, Ibsp, and Alpl.
Finally, HA maintains the stemness of osteoprogenitors by inducing the
expression of the transcription factor Sox2 and its direct targets Yap1 and
Bmi1. Inhibited Wnt signaling and induced TGF-β/FGF signaling may
contribute to the self-renewal capability of HA-treated osteoprogenitors.
Taken together, our results suggest a prominent role of HA in inducing the
growth, and maintaining the stemness and differentiation potential of
mesenchymal stromal and pre-osteoblastic cells. Solid lines in the model
represent direct evidence and common knowledge; dashed lines display
links that are solidly supported by literature reports. For more details on
the displayed links between the HA-induced functionalities, please refer
to the text
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expression of Sox2 and its downstream targets Yap1 and
Bmi1 as critical stemness genes, (3) inhibition of Wnt signal-
ing, and (4) suppression of genes typical for mineralized bone
matrix. The multiple effects of the investigated HAs on the
behavior and function of the two progenitor cell lines could be
considered as either independent or strongly interrelated (po-
tential interrelations between the HA-induced effects de-
scribed in the present study are displayed in Fig. 8).
Controversial effects of HA on both cellular prolifera-
tion and osteogenic differentiation in vitro have been re-
ported in the literature [11–15, 17, 61]. The nature of the
observed effects is tightly related to the cellular context,
concentration and MWof HA, and mode of delivery of HA
to the cell culture [18]. Here, we reported a pro-
proliferative effect of HAs with a MW close to that of
the physiological HA present in healthy solid tissues
(1000–6000 kDa) [3]. In our experiments, the HA prepa-
rations were applied to cell cultures diluted by 3.5–4.5-
fold, thus considering their potential dilution by patient’s
blood and saliva at the defect side. Moreover, the positive
effects on the cellular proliferation have been observed for
both the non-crosslinked HA1 and the crosslinked HA2
formulation. The pro-proliferative effects of the investi-
gated HAs could be mechanistically explained by the in-
creased expression of genes encoding TGF-β1 and FGF-1
growth factors as well as the induction of Smad2 and Erk1/
2 signaling in the HA-treated ST2 and MC3T3-E1 cells.
TGF-β1 and FGF signaling pathways have been reported
to induce cellular proliferation in the osteoblast lineage
[40, 62]. Furthermore, TGF-β1 has been recognized as a
key promoter of collagen expression [63] and early stages
of bone formation, namely bone matrix production [32,
39]. FGFs, in their turn, were shown to prominently in-
duce the osteopontin-encoding Spp1 gene in various cell
types [64–66], but they negatively influenced the expres-
sion of Col1 [67]. This suggests that TGF-β1 and FGF-1
might not be the only factors induced by HA that could
explain the upregulation of Spp1 and Col1 genes in the
HA-treated osteoprogenitors. The same is valid for the
observed suppression of intermediate and late osteogenic
differentiation markers upon HA treatment, which might
not solely result by the downregulation of BMP-induced
Smad phosphorylation or inhibition of Wnt signaling.
Inhibited osteogenesis upon HA treatment might be an
end point achieved by several mechanisms, e.g., we can-
not exclude a negative effect of HA on the insulin-like
growth factor (IGF) signaling pathway that is known to
induce osteoblast differentiation [68]. A number of animal
and human genetics studies have identified a role for Wnt
signaling in promoting osteoblast function and bone for-
mation, and Wnt signals often cooperate with BMPs to
induce osteoblast differentiation [69]. Thus, the downreg-
ulation of Wnt signaling observed in our study is an
important mechanism by which HA inhibits late osteogen-
ic differentiation marker expression.
Consequently, we showed that HA induces the expression
of the transcription factor Sox2 and its direct targets Yap1 and
Bmi1. Yap1 (Yes-associated protein 1) is a transcriptional co-
activator of the TEAD transcription factors, and Bmi1 is a
polycomb complex transcriptional repressor. All three genes
are implicated in maintaining pluripotency and self-renewal in
embryonic [48, 52, 53] as well as in adult stem cells [49–51],
suggesting a prominent role of HA in maintaining the
stemness and differentiation potential of mesenchymal stro-
mal and pre-osteoblastic cells. Our in vitro study has certain
limitations, e.g., further research is needed to elucidate if HA
may control cell fate decisions during bone formation in vivo.
It may be speculated that HA provides the time for progenitor
cells to proliferate and reach a critical cell mass before differ-
entiation is initiated. Differentiation can then be triggered by
other factors at the defect side, e.g., by signals coming from
autologous bone used as a bone graft material [32]. It has
already been shown that autologous bone combined with an
esterified HA preparation accelerated new bone formation af-
ter surgical treatment of infrabony defects [26].
In conclusion, our data strongly suggest that addition
of HA to deficient bone or bony defects during implant or
reconstructive periodontal surgeries might be a useful
approach for expanding adult stem cells without losing
their replicative and differentiation capabilities. The
ability of the two investigated HAs to expand the pool
of osteoprogenitors and to maintain their stemness could
be combined with the possibility for triggering osteogen-
ic differentiation either by manipulation of HA concen-
tration and/or MW or by combination of HA with autol-
ogous bone or another osteoinductive bone substitute
material, thus providing a complete solution for bone
regeneration during reconstructive periodontal and im-
plant surgeries.
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